Navigation Links
Folic acid lowers blood arsenic levels in Bangladesh
Date:10/10/2007

A new study conducted in Bangladesh finds that folic acid supplements can dramatically lower blood arsenic levels in individuals chronically exposed to arsenic-contaminated drinking water. Arsenic is a toxic element that is naturally present in some soils and water. Arsenic-contaminated drinking water is currently a significant public health problem in at least 70 countries, including several developing countries and also parts of the United States. Chronic arsenic exposure is associated with increased risk for skin, liver and bladder cancers, skin lesions, cardiovascular disease, and other adverse health outcomes. The study was funded by the National Institute of Environmental Health Sciences (NIEHS) at the National Institutes of Health (NIH).

Researchers found that treatment with 400 micrograms a day of folic acid, the U.S. Recommended Dietary Allowance, reduced total blood arsenic levels in a Bangladesh study population by 14 percent. Folate is a B vitamin found in leafy vegetables, citrus fruits, beans, and whole grains. Folic acid can also be taken as a vitamin supplement, and in the United States, it is added to flour and other fortified foods. The researchers found that folate deficiency is very common in Bangladesh, where the study was conducted, but is not as problematic in the United States due to folate fortification. Additional studies are needed to determine if folic acid similarly lowers blood arsenic in populations where folate deficiency is less common, such as in the United States.

William Suk, Ph.D., Acting Deputy Director of the NIEHS discussed the significance of this work in Bangladesh to the U.S. He explains that arsenic contamination of groundwater is one of the five most common inorganic compounds found at Superfund sites and is present at over 70 percent of the sites. Because of the prevalence of arsenic, the SBRP has placed an emphasis on supporting arsenic-related research in heavily affected areas all over t
'/>"/>

Contact: Robin Mackar
rmackar@niehs.nih.gov
919-541-0073
NIH/National Institute of Environmental Health Sciences
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Medical whistleblowers speak out
2. Bumblebees copy one another when contending with unfamiliar flowers
3. FDA: Highly Unlikely Green Tea Lowers Cancer Risk
4. Reducing antibiotic use lowers rates of drug-resistant bacteria
5. Recreating Flowers for Algernon with a happy ending
6. AIDS drug from sunflowers
7. How nice, brown rice: Study shows rice bran lowers blood pressure in rats
8. Wild bees and the flowers they pollinate are disappearing together
9. Genetic snooze button governs timing of spring flowers
10. Hair-growth drug artificially lowers PSA levels in prostate cancer screening, study finds
11. How did bilaterally symmetric flowers evolve from radially symmetric ones?

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2009)...ember 18, 2009 -- A butterfly,s proboscis looks li...-- but it works more like a paper towel, according...pes to borrow the tricks of this piece of insect a...uid inside of cells. , Kornev will present his w...erican Physical Society,s (APS) Division of Fluid ...
(Date:11/21/2009)...vember 20,2009 / b3c newswire / - KINAXO Biotech...cing round, gaining two new investors in the compa...NAXO reports that Jrgen Schumacher has been electe..., KINAXO shareholders Axel Ullrich, Hellmut Kirc...tutional investors Mountain Partners, BioM, High-T...
(Date:11/20/2009)...ve all read studies about the health benefits of h...e molecular level, where amino acids known as cyst...le than when paired up with other cysteines. , N...ng with colleagues in Belgium, have discovered a n...es. The research appears in the Nov. 20 issue of t...
Breaking Biology News(10 mins):KINAXO Completes Financing Round to Enhance Biomarker Development 2KINAXO Completes Financing Round to Enhance Biomarker Development 3Saving the single cysteine: New antioxidant system found 2Derma Sciences Announces First Commercial Sales of BIOGUARD 28TM 29 Barrier Dressings 49751 1Derma Sciences Announces First Commercial Sales of BIOGUARD 28TM 29 Barrier Dressings 49751 2Derma Sciences Announces First Commercial Sales of BIOGUARD 28TM 29 Barrier Dressings 49751 3Derma Sciences Announces First Commercial Sales of BIOGUARD 28TM 29 Barrier Dressings 49751 4Biovista Inc Announces Positive Efficacy Results in a Pre Clinical Trial of its BVA 601 Repositioned Drug for Epilepsy 12744 1Biovista Inc Announces Positive Efficacy Results in a Pre Clinical Trial of its BVA 601 Repositioned Drug for Epilepsy 12744 2B Braun Medical Inc Recognized by Industry for Manufacturing Influential Medical Devices 12742 1B Braun Medical Inc Recognized by Industry for Manufacturing Influential Medical Devices 12742 2B Braun Medical Inc Recognized by Industry for Manufacturing Influential Medical Devices 12742 3B Braun Medical Inc Recognized by Industry for Manufacturing Influential Medical Devices 12742 4
...xperts from Queen,s University Belfast have develo...quired infections that are resistant to antibiotic...t only kill colonies of these dangerous microbes, ... of these new antimicrobial agents was carried out...niversity Ionic Liquid Laboratories (QUILL) Resear...
...onserving Australia,s most endangered snake might ...posed. , The last remaining populations of broad-...woodland that is destroying their habitat, a study...tanford University (USA) has shown. , "Broad-head...ithin 200 km of Sydney, and those small communitie...
...IAMI University of Miami,s (UM,s) Rosenstiel Scho... announce they have received two grants totaling $...und. One award for $51,000 will be used to re-ener...ogram aboard Royal Caribbean International,s Explo...ted with ocean and atmospheric science laboratorie...
Other Biology News:Queen's scientists find new way to battle MRSA 2Australia's most endangered snake might need burning 2The University of Miami receives grants from Royal Caribbean Cruises Ltd.'s Ocean Fund 2
(Date:11/19/2009)... BLAUVELT, N.Y., Nov. 19 Dr. Mate ...xtract, responds to a press release issued on Nove...ian company for making false and self-serving stat...ces. ,, Dr. Hidvegi stated from his office in ...at research on Avemar does not apply to AveULTRA, ...
(Date:11/19/2009)... NEW YORK, Nov. 19 NeoSt...it has sent the following letter to its shareholde...er 30, 2009, of China Biopharmaceuticals Holdings,...pany based in the People,s Republic of China. The ... Suzhou Eyre Pharmaceutical Co. Ltd., CHBP,s prima...
(Date:11/19/2009)..., MALVERN, Pa. and WALTHAM, Mass., Nov. 19 /PRN...Decision Resources find that the leading driver of...urope is broad-spectrum activity against gram-posi...ty of organisms that can cause nosocomial pneumoni...ook primarily for agents that provide appropriate ...
(Date:11/19/2009)... MONTREAL, Nov. 19 /PRNewswire/ - Aegera Therapeut...atient in a randomized Phase 2B study of AEG35156,...elopment for multiple oncology indications. ,, ...e 2 Study of the X-Linked Inhibitor of Apoptosis (... High-dose Cytarabine and Idarubicin in AML Follow...
Breaking Biology Technology:American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2
...Hospitalist Company, Inc. (Nasdaq: IPCM ), a lead... today reaffirmed its guidance for full year 2008,... million and full year,2008 earnings per adjusted ...ncurred in the first quarter related to the Compan...ent the impact of acquisitions, the Company,typica...
...nounced today,that it received FDA 510(k) clearanc...em for Positron Emission Tomography/Computed Tomog...TM) PET Infusion System is the,first infusion syst...FDG,delivery process., (Logo: http://www.newscom...mating and controlling the FDG delivery process, t...
...reholders Believe It Reflects,Unwillingness To Con...ck of Industry Knowledge...on BetterBiovail.com All Shareholders Urged to Se... June 17 The Concerned Shareholders,of Biovail Co...a refusal by,Biovail CEO William Wells to particip...
Other Biology Technology:IPC The Hospitalist Company, Inc. Reaffirms Guidance for 2008 2IPC The Hospitalist Company, Inc. Reaffirms Guidance for 2008 3IPC The Hospitalist Company, Inc. Reaffirms Guidance for 2008 4MEDRAD Receives FDA 510(k) Clearance for FDG Infusion System 2MEDRAD Receives FDA 510(k) Clearance for FDG Infusion System 3Biovail Concerned Shareholders Want Open Debate 2Biovail Concerned Shareholders Want Open Debate 3
Rabbit Anti-Human NIRF Polyclonal Antibody, Unconjugated from Abcam
Acc I from Invitrogen
SexA I from New England Biolabs
Psp1406 I from Takara Mirus Bio
Biology Products: